Merrimack Pharmaceuticals announced it will discontinue the development of an experimental treatment for pancreatic cancer after the drug failed to meet the main and secondary goals of a mid-stage trial.
The treatment, MM-141, was being studied in addition to standard-of-care treatment for patients with previously untreated metastatic pancreatic cancer. The study did not meet its primary or secondary efficacy endpoints in patients who received MM-141 in combination with nab-paclitaxel and gemcitabine, compared to nab-paclitaxel and gemcitabine alone.
The drugmaker has two promising breast cancer clinical programs, MM-121 and MM-310, with data readouts expected in 2018.
Read the press release